Getein Biotech Inc
SSE:603387

Watchlist Manager
Getein Biotech Inc Logo
Getein Biotech Inc
SSE:603387
Watchlist
Price: 9.21 CNY 5.26% Market Closed
Market Cap: ¥4.7B

Income Statement

Earnings Waterfall
Getein Biotech Inc

Income Statement
Getein Biotech Inc

Rotate your device to view
Income Statement
Currency: CNY
Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Revenue
Interest Expense
0
0
0
0
0
0
0
0
1
2
1
3
5
6
6
7
8
9
14
15
17
19
17
20
17
17
17
14
15
15
0
13
0
0
Revenue
411
N/A
451
+10%
489
+8%
540
+10%
587
+9%
612
+4%
686
+12%
749
+9%
818
+9%
863
+6%
968
+12%
910
-6%
907
0%
1 101
+21%
1 123
+2%
1 251
+11%
1 344
+7%
1 283
-5%
1 402
+9%
1 696
+21%
1 775
+5%
1 857
+5%
1 822
-2%
1 635
-10%
1 552
-5%
1 446
-7%
1 369
-5%
1 306
-5%
1 283
-2%
1 248
-3%
1 165
-7%
1 087
-7%
1 060
-3%
1 043
-2%
Gross Profit
Cost of Revenue
(79)
(82)
(89)
(105)
(122)
(132)
(144)
(188)
(221)
(250)
(265)
(265)
(279)
(375)
(414)
(482)
(506)
(468)
(485)
(565)
(613)
(621)
(672)
(595)
(556)
(537)
(465)
(443)
(427)
(404)
(374)
(336)
(339)
(338)
Gross Profit
333
N/A
369
+11%
400
+8%
435
+9%
465
+7%
480
+3%
542
+13%
561
+3%
597
+6%
614
+3%
703
+15%
645
-8%
628
-3%
726
+16%
709
-2%
769
+8%
838
+9%
814
-3%
916
+13%
1 132
+24%
1 161
+3%
1 236
+6%
1 150
-7%
1 041
-10%
996
-4%
909
-9%
904
-1%
864
-4%
857
-1%
844
-1%
790
-6%
751
-5%
721
-4%
704
-2%
Operating Income
Operating Expenses
(156)
(170)
(187)
(202)
(219)
(238)
(293)
(295)
(319)
(337)
(336)
(323)
(323)
(333)
(379)
(400)
(422)
(443)
(493)
(529)
(560)
(585)
(654)
(677)
(711)
(726)
(675)
(660)
(626)
(597)
(545)
(564)
(562)
(563)
Selling, General & Administrative
(157)
(159)
(140)
(178)
(197)
(211)
(211)
(240)
(240)
(248)
(245)
(234)
(228)
(239)
(270)
(299)
(309)
(316)
(324)
(366)
(391)
(408)
(408)
(429)
(458)
(484)
(431)
(472)
(456)
(423)
(342)
(373)
(365)
(375)
Research & Development
0
(13)
(52)
0
0
(40)
(78)
(69)
(91)
(102)
(101)
(107)
(115)
(119)
(114)
(133)
(144)
(152)
(156)
(178)
(185)
(196)
(215)
(227)
(231)
(232)
(207)
(207)
(203)
(195)
(171)
(181)
(172)
(170)
Depreciation & Amortization
0
0
(11)
0
0
0
(14)
0
0
0
(16)
0
0
0
(19)
0
0
0
(31)
0
0
0
(49)
0
0
0
(68)
0
0
0
(68)
0
0
0
Other Operating Expenses
1
1
15
(24)
(22)
13
9
14
12
13
26
18
20
26
24
31
31
26
19
16
17
19
18
(21)
(22)
(11)
31
19
32
21
36
(10)
(25)
(18)
Operating Income
177
N/A
198
+12%
213
+8%
234
+9%
246
+5%
242
-2%
249
+3%
266
+7%
278
+4%
276
-1%
368
+33%
322
-13%
305
-5%
393
+29%
330
-16%
369
+12%
415
+13%
372
-11%
423
+14%
603
+42%
602
0%
651
+8%
496
-24%
364
-27%
285
-22%
183
-36%
229
+26%
203
-11%
230
+13%
247
+7%
245
-1%
187
-24%
159
-15%
141
-11%
Pre-Tax Income
Interest Income Expense
4
6
10
16
24
31
34
39
36
33
31
30
24
18
44
30
45
55
32
19
33
45
67
94
89
89
66
64
56
42
42
38
43
50
Non-Reccuring Items
0
0
0
0
0
0
(0)
0
(0)
(0)
1
1
1
2
4
1
1
0
(2)
1
1
1
(0)
(0)
(0)
1
10
1
(1)
(1)
(34)
1
2
3
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
(0)
0
0
0
(0)
0
0
0
(0)
0
0
0
(0)
0
0
0
(1)
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
11
4
1
4
1
1
5
5
5
3
(3)
(4)
(4)
(4)
(4)
(2)
(3)
(2)
(1)
(3)
(2)
(2)
(3)
(4)
(4)
(2)
0
(1)
(1)
(3)
1
(6)
(7)
(7)
Pre-Tax Income
192
N/A
208
+9%
224
+8%
253
+13%
271
+7%
274
+1%
287
+5%
310
+8%
318
+3%
312
-2%
396
+27%
348
-12%
326
-7%
409
+26%
374
-9%
398
+6%
458
+15%
425
-7%
452
+6%
621
+37%
634
+2%
695
+10%
560
-19%
454
-19%
369
-19%
270
-27%
305
+13%
267
-12%
284
+6%
285
+0%
253
-11%
221
-13%
198
-10%
187
-5%
Net Income
Tax Provision
(27)
(28)
(30)
(34)
(36)
(37)
(37)
(38)
(39)
(37)
(46)
(41)
(33)
(42)
(44)
(44)
(53)
(54)
(40)
(56)
(66)
(64)
(56)
(46)
(27)
(13)
(21)
(20)
(21)
(26)
(24)
(16)
(16)
(16)
Income from Continuing Operations
165
180
194
220
235
237
251
271
279
275
350
307
293
367
330
354
406
371
412
564
568
631
504
408
342
257
284
247
263
259
230
205
182
171
Income to Minority Interest
0
0
0
0
(0)
(0)
(1)
(3)
(6)
(7)
(10)
(10)
(11)
(29)
(26)
(30)
(26)
(10)
(13)
(9)
(10)
(10)
(5)
(6)
(4)
(4)
(4)
(3)
(6)
(6)
(6)
(3)
4
11
Net Income (Common)
165
N/A
180
+9%
194
+8%
220
+13%
235
+7%
236
+1%
250
+6%
268
+7%
273
+2%
268
-2%
340
+27%
298
-12%
282
-5%
338
+20%
305
-10%
324
+6%
380
+17%
361
-5%
399
+11%
555
+39%
558
+1%
621
+11%
499
-20%
402
-19%
338
-16%
253
-25%
280
+11%
244
-13%
258
+6%
253
-2%
224
-12%
202
-10%
186
-8%
182
-2%
EPS (Diluted)
0.85
N/A
0.74
-13%
0.88
+19%
0.84
-5%
0.9
+7%
0.92
+2%
0.96
+4%
1.03
+7%
1.04
+1%
1.02
-2%
1.3
+27%
1.14
-12%
1.08
-5%
1.26
+17%
1.17
-7%
1.24
+6%
0.74
-40%
0.72
-3%
0.79
+10%
1.09
+38%
1.1
+1%
1.21
+10%
0.98
-19%
0.79
-19%
0.66
-16%
0.5
-24%
0.55
+10%
0.48
-13%
0.51
+6%
0.5
-2%
0.44
-12%
0.4
-9%
0.37
-8%
0.36
-3%